These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 21083673)

  • 1. Randomised clinical trial: high-dose acid suppression for chronic cough - a double-blind, placebo-controlled study.
    Shaheen NJ; Crockett SD; Bright SD; Madanick RD; Buckmire R; Couch M; Dellon ES; Galanko JA; Sharpless G; Morgan DR; Spacek MB; Heidt-Davis P; Henke D
    Aliment Pharmacol Ther; 2011 Jan; 33(2):225-34. PubMed ID: 21083673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic cough and esomeprazole: a double-blind placebo-controlled parallel study.
    Faruqi S; Molyneux ID; Fathi H; Wright C; Thompson R; Morice AH
    Respirology; 2011 Oct; 16(7):1150-6. PubMed ID: 21707852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reflux episodes detected by impedance in patients on and off esomeprazole: a randomised double-blinded placebo-controlled crossover study.
    Moawad FJ; Betteridge JD; Boger JA; Cheng FK; Belle LS; Chen YJ; Maydonovitch CL; Wong RK
    Aliment Pharmacol Ther; 2013 May; 37(10):1011-8. PubMed ID: 23560727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of esomeprazole for treatment of poorly controlled asthma.
    ; Mastronarde JG; Anthonisen NR; Castro M; Holbrook JT; Leone FT; Teague WG; Wise RA
    N Engl J Med; 2009 Apr; 360(15):1487-99. PubMed ID: 19357404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reflux pattern and role of impedance-pH variables in predicting PPI response in patients with suspected GERD-related chronic cough.
    Ribolsi M; Savarino E; De Bortoli N; Balestrieri P; Furnari M; Martinucci I; Casale M; Greco F; Salvinelli F; Savarino V; Marchi S; Cicala M
    Aliment Pharmacol Ther; 2014 Oct; 40(8):966-73. PubMed ID: 25109844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Randomized Placebo-Controlled
    Sierra-Arango F; Castaño DM; Forero JD; Pérez-Riveros ED; Ardila Duarte G; Botero ML; Cárdenas A; De la Hoz-Valle J
    Can J Gastroenterol Hepatol; 2019; 2019():3926051. PubMed ID: 31929980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of Clinical Predictors of Resolution of Sleep Disturbance Related to Frequent Nighttime Heartburn and Acid Regurgitation Symptoms in Individuals Taking Esomeprazole 20 mg or Placebo.
    Johnson DA; Le Moigne A; Li J; Pollack C; Nagy P
    Clin Drug Investig; 2016 Jul; 36(7):531-8. PubMed ID: 27074935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IW-3718 Reduces Heartburn Severity in Patients With Refractory Gastroesophageal Reflux Disease in a Randomized Trial.
    Vaezi MF; Fass R; Vakil N; Reasner DS; Mittleman RS; Hall M; Shao JZ; Chen Y; Lane L; Gates AM; Currie MG
    Gastroenterology; 2020 Jun; 158(8):2093-2103. PubMed ID: 32092310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Characteristics of Patients with Gastroesophageal Reflux Disease Refractory to Proton Pump Inhibitors and the Effects of Switching to 20 mg Esomeprazole on Reflux Symptoms and Quality of Life.
    Takeshima F; Hashiguchi K; Onitsuka Y; Tanigawa K; Minami H; Matsushima K; Akazawa Y; Shiozawa K; Yamaguchi N; Taura N; Ohnita K; Ichikawa T; Isomoto H; Nakao K
    Med Sci Monit; 2015 Dec; 21():4111-21. PubMed ID: 26719012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomised clinical trial: daily pantoprazole magnesium 40 mg vs. esomeprazole 40 mg for gastro-oesophageal reflux disease, assessed by endoscopy and symptoms.
    Moraes-Filho JP; Pedroso M; Quigley EM;
    Aliment Pharmacol Ther; 2014 Jan; 39(1):47-56. PubMed ID: 24299323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomised clinical trial: arbaclofen placarbil in gastro-oesophageal reflux disease--insights into study design for transient lower sphincter relaxation inhibitors.
    Vakil NB; Huff FJ; Cundy KC
    Aliment Pharmacol Ther; 2013 Jul; 38(2):107-17. PubMed ID: 23721547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults.
    Chang AB; Lasserson TJ; Gaffney J; Connor FL; Garske LA
    Cochrane Database Syst Rev; 2011 Jan; 2011(1):CD004823. PubMed ID: 21249664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence and clinical characteristics of refractoriness to optimal proton pump inhibitor therapy in non-erosive reflux disease.
    Ribolsi M; Cicala M; Zentilin P; Neri M; Mauro A; Efthymakis K; Petitti T; Savarino V; Penagini R
    Aliment Pharmacol Ther; 2018 Nov; 48(10):1074-1081. PubMed ID: 30294924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arbaclofen placarbil in GERD: a randomized, double-blind, placebo-controlled study.
    Vakil NB; Huff FJ; Bian A; Jones DS; Stamler D
    Am J Gastroenterol; 2011 Aug; 106(8):1427-38. PubMed ID: 21519360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomised clinical trial: oesophageal radiofrequency energy delivery versus sham for PPI-refractory heartburn.
    Zerbib F; Sacher-Huvelin S; Coron E; Coffin B; Melchior C; Ponchon T; Cholet F; Chabrun E; Vavasseur F; Gorbatchef C; Zalar A; Mion F; Robaszkiewicz M; Le Rhun M; Leroy M; Paul Galmiche J; Bruley des Varannes S
    Aliment Pharmacol Ther; 2020 Aug; 52(4):637-645. PubMed ID: 32656869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized clinical trial: A double-blind, proof-of-concept, phase 2 study evaluating the efficacy and safety of vonoprazan 20 or 40 mg versus esomeprazole 40 mg in patients with symptomatic gastro-esophageal reflux disease and partial response to a healing dose of a proton-pump inhibitor.
    Tack J; Vladimirov B; Horny I; Chong CF; Eisner J; Czerniak R; Takanami Y
    Neurogastroenterol Motil; 2023 Jan; 35(1):e14468. PubMed ID: 36178335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of once-daily esomeprazole for the treatment of gastroesophageal reflux disease in neonatal patients.
    Davidson G; Wenzl TG; Thomson M; Omari T; Barker P; Lundborg P; Illueca M
    J Pediatr; 2013 Sep; 163(3):692-8.e1-2. PubMed ID: 23800403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of add-on therapy with domperidone vs alginic acid in proton pump inhibitor partial response gastro-oesophageal reflux disease in systemic sclerosis: randomized placebo-controlled trial.
    Foocharoen C; Chunlertrith K; Mairiang P; Mahakkanukrauh A; Suwannaroj S; Namvijit S; Wantha O; Nanagara R
    Rheumatology (Oxford); 2017 Feb; 56(2):214-222. PubMed ID: 27179107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of gastroesophageal reflux disease symptoms and effects of esomeprazole on the quality of life related to reflux and dyspepsia in patients on maintenance hemodialysis.
    Namikoshi T; Harada K; Hatta H; Tokura T; Oshiro Y; Nishizaki T; Obata T; Mori M; Fueki T; Fujimoto S; Haruna Y; Kuwabara A; Yorimitsu D; Ihoriya C; Kadoya H; Itano S; Fujimoto Y; Komai N; Sasaki T; Kashihara N
    Clin Exp Nephrol; 2016 Feb; 20(1):134-42. PubMed ID: 26026991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of proton pump inhibitors in the management of gastroesophageal reflux disease-related asthma and chronic cough.
    Kiljander TO
    Am J Med; 2003 Aug; 115 Suppl 3A():65S-71S. PubMed ID: 12928078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.